📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: BioCryst

1.1 - Company Overview

BioCryst Logo

BioCryst

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor for prophylaxis to prevent hereditary angioedema attacks in adults and pediatric patients 12 years and older, and RAPIVAB (peramivir injection) for acute uncomplicated influenza; also developing BCX10013 (oral Factor D inhibitor) and an oral C5 inhibitor for complement-mediated diseases, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema.

Products and services

  • ORLADEYO (berotralstat): Oral plasma kallikrein inhibitor delivering prophylaxis to prevent hereditary angioedema attacks in adults and pediatric patients 12 years and older
  • RAPIVAB (peramivir injection): Injectable antiviral indicated for treating acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than two days
  • Oral C5 Inhibitor: Investigational drug candidate engineered to inhibit the C5 protein driving downstream terminal functions in complement-mediated diseases

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to BioCryst

Imara Logo

Imara

HQ: United States Website
  • Description: Provider of novel therapeutics for people living with sickle cell disease and hemoglobinopathies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Imara company profile →
BioMarin Logo

BioMarin

HQ: United States Website
  • Description: Provider of innovative biopharmaceuticals for serious diseases and medical conditions, developing and commercializing them.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BioMarin company profile →
Sobi Logo

Sobi

HQ: Sweden Website
  • Description: Provider of orphan and specialty pharmaceuticals for rare and life-threatening diseases, developing, marketing and distributing treatments across haematology, cardiology, infectious and metabolic disorders, genetic diseases, and conditions in immunocompromised patients; portfolio includes Alprolix, Elocta, Synagis, Kineret, Orfadin, and Gamifant.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sobi company profile →
Chiasma Logo

Chiasma

HQ: United States Website
  • Description: Provider of biopharmaceutical solutions developing oral drugs for orphan diseases using proprietary Transient Permeability Enhancer technology to convert approved injectables to oral formulations, potentially enabling new indications and enhanced absorption by promoting delivery to the GI wall and liver.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Chiasma company profile →
PTC Therapeutics Logo

PTC Therapeutics

HQ: United States Website
  • Description: Provider of biopharmaceutical therapies. Products include EMFLAZA for Duchenne muscular dystrophy; TRANSLARNA for Duchenne muscular dystrophy with a nonsense mutation; EVRYSDI for spinal muscular atrophy; TEGSEDI for hereditary transthyretin amyloidosis polyneuropathy; WAYLIVRA for familial chylomicronemia syndrome; and UPSTAZA gene therapy for aromatic L-amino acid decarboxylase deficiency.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full PTC Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for BioCryst

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to BioCryst

2.2 - Growth funds investing in similar companies to BioCryst

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for BioCryst

4.2 - Public trading comparable groups for BioCryst

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to BioCryst

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About BioCryst

What does BioCryst do?

BioCryst is a provider of ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor for prophylaxis to prevent hereditary angioedema attacks in adults and pediatric patients 12 years and older, and RAPIVAB (peramivir injection) for acute uncomplicated influenza; also developing BCX10013 (oral Factor D inhibitor) and an oral C5 inhibitor for complement-mediated diseases, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema.

Who are BioCryst's competitors?

BioCryst's competitors and similar companies include Imara, BioMarin, Sobi, Chiasma, and PTC Therapeutics.

Where is BioCryst headquartered?

BioCryst is headquartered in United States.

How many employees does BioCryst have?

BioCryst has 1,000 employees 🔒.

When was BioCryst founded?

BioCryst was founded in 2010 🔒.

What sector and industry vertical is BioCryst in?

BioCryst is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for BioCryst

Who are the top strategic acquirers in BioCryst's sector and industry

Top strategic M&A buyers and acquirers in BioCryst's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for BioCryst?

Top strategic M&A buyers groups and sectors for BioCryst include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in BioCryst's sector and industry vertical

Which are the top PE firms investing in BioCryst's sector and industry vertical?

Top PE firms investing in BioCryst's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in BioCryst's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in BioCryst's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in BioCryst's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to BioCryst include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in BioCryst's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for BioCryst?

The key public trading comparables and valuation benchmarks for BioCryst include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for BioCryst for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for BioCryst with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in BioCryst's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for BioCryst with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in BioCryst's' sector and industry vertical?

Access recent funding rounds and capital raises in BioCryst's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for BioCryst